Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MYGN with free AI briefings, catalyst countdowns, and dilution alerts.

MYGN · MYRIAD GENETICS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$107.1M Cash on Hand
43.4mo Cash Runway
Follow MYGN by email Get an email when MYGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MYGN, unsubscribe in one click. Privacy

📣 What MYGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Single agent chemotherapy Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity Phase 3 · NCT02282020 Completed
Sacituzumab Tirumotecan (SKB264) Solid Tumor Phase 2 · NCT05642780 Active not recruiting
Cediranib Recurrent Platinum Resistant Ovarian Cancer Phase 2 · NCT02889900 Completed
Pamiparib Locally Advanced or Metastatic Solid Tumors Phase 1 · NCT03150810 Completed
Apoptosis Inducer MPC-2130 Cancer Phase 1 · NCT00387153 Terminated
Melphalan Pancreatic Adenocarcinoma Metastatic Phase 1 · NCT04150042 Recruiting
Carmustine Pancreatic Adenocarcinoma Metastatic Phase 1 · NCT04150042 Recruiting
Ascorbic Acid Pancreatic Adenocarcinoma Metastatic Phase 1 · NCT04150042 Recruiting

Also used in these trials (approved or third-party drugs, not MYGN's own candidates): Abiraterone Acetate, Olaparib, Prednisone, Enzalutamide, Niraparib, Rucaparib, Durvalumab, Carboplatin, Bevacizumab, Talazoparib, Temozolomide, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MYGN holds $107.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.4M/quarter from operations, an estimated runway of 43.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MYGN files for a raise →

👥 Who Owns MYGN

Insiders 6.1% Other 5%+ holders 7% Institutions (261 holders) 86.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock Portfolio Management LLC Institution (13G, 5%+) 8,219,061 8.57% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 7,976,163 8.32% 2026-03-31
Millennium Management LLC 5%+ holder (13G) 6,700,158 6.98% 2025-12-31
STATE STREET CORPORATION Institution (13G, 5%+) 4,985,060 5.20% 2026-06-30
Samraat S. Raha
President and CEO, Director
Insider 1,068,083 1.11% 2026-06-11
Mark Verratti
Chief Operating Officer · +146,933 options
Insider 629,646 0.66% 2026-04-14
Brian J Donnelly
Chief Commercial Officer · +236,167 options
Insider 573,363 0.60% 2026-09-16
Vishal Sikri
EVP, Commercial · +53,236 options
Insider 351,224 0.37% 2026-09-16
Jennifer Lynne Fox
Chief Legal & Corp Strategy · +139,267 options
Insider 345,334 0.36% 2026-11-01
S. Louise Phanstiel
Director
Insider 341,652 0.36% 2026-06-04
Dale Muzzey
Chief Scientific Officer · +92,632 options
Insider 326,310 0.34% 2026-04-14
Benjamin Richard Wheeler
Chief Financial Officer · +121,379 options
Insider 287,193 0.30% 2026-09-21

Share count 95,922,196 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MYGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MYGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.